GlassScriptPhysician profile
Victor M Chavez
NPI 1700830593
$51,855.94
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $5,832 · 2021: $14K · 2022: $8,787.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $42,172.26 | 2019-2022 | |
| Intuitive Surgical, INC. | $5,067.71 | 2021-2022 | |
| Viiv Healthcare Company | $4,000.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $131.98 | 2019 | |
| Pulmonx Corporation | $102.21 | 2019 | |
| Ethicon INC. | $75.00 | 2019 | |
| Sunovion Pharmaceuticals INC. | $69.16 | 2019 | |
| Csl Behring | $47.64 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $25.23 | 2019 | |
| Bard Access Systems, INC. | $24.19 | 2019 | |
| Merck Sharp & Dohme LLC | $23.61 | 2019 | |
| Philips North America LLC | $19.58 | 2019 | |
| United Therapeutics Corporation | $17.81 | 2019 | |
| Mylan Specialty L.P. | $17.51 | 2019 | |
| Advanced Respiratory, INC | $14.54 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Circassia INC. | $12.40 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.83 | 2019 | |
| Grifols USA, LLC | $11.79 | 2019 | |
| Pfizer INC. | $11.49 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victor Chavez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.